Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Takeda
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01467700
First received: November 4, 2011
Last updated: July 18, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to determine the efficacy and safety of Ramelteon, once daily (QD), sublingual (SL), in adult patients with acute depressive episodes associated with Bipolar I disorder.


Condition Intervention Phase
Acute Depressive Episode
Drug: Ramelteon SL
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) in the Treatment of Acute Depressive Episodes Associated With Bipolar I Disorder in Adult Patients Who Are on Lithium and/or Valproate

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The change between MADRS score at week 6 relative to baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.


Secondary Outcome Measures:
  • Change from Baseline in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) Short Form Total Score at Week 6 [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF) is a self-administered, 16-item questionnaire to assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning. The 16-item short form of the Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) has been used to measure satisfaction with various domains of life functioning, such as social relationships, living/housing, physical health, medication, and global satisfaction. The questionnaire consists of 16 items rated by the patient on a 5-point scale. Of these, 14 items are summed to produce a total quality of life score with a maximum of 70 points. In addition, there are two global items that are scored individually. These items rate satisfaction with study medication and overall life satisfaction. The questionnaire is usually scored as a percent of the total possible score, with higher scores indicating better health status.

  • MADRS Response at Week 6, with Response Defined as a ≥ 50% Decrease in the MADRS Total Score from Baseline. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The MADRS response at week 6 relative to baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.

  • Change from Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 6. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The YMRS total score at week 6 relative to baseline. YMRS is a four item scale to assess manic symptoms, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe), with 7 items rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe) with higher scores reflecting greater levels of mania. The YMRS total score is calculated as the sum of the 11 individual item scores and ranges from 0-60.

  • Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6. [ Time Frame: 6 Weeks. ] [ Designated as safety issue: No ]
    The CGI-I assesses the clinician's impression of the participant's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change relative to baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater severity of illness.

  • Change in Clinical Global Impression Scale-Severity (CGI-S) from Baseline to Week 6. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The CGI-S at week 6 relative to baseline. The CGI-S assesses the clinician's impression of the participant's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill). Higher scores indicate greater severity of illness.

  • MADRS Remission at Week 6, with remission defined as a MADRS Total Score ≤10. [ Time Frame: 6 Weeks. ] [ Designated as safety issue: No ]
    MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.

  • Change from Baseline in the Quick Inventory of Depressive Symptomatology - Self-Rated16 (QIDS-SR16) Total Score at Week 6. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The 16 item Quick Inventory of Depressive Symptomatology - Self Rated (QIDS-SR16) version is designed to assess the severity of depressive symptoms. The QIDS-SR16 assesses all the criterion symptom domains designated by the American Psychiatry Association Diagnostic and Statistical Manual of Mental Disorders - 4th edition, DSM-IV, to diagnose a major depressive episode. QIDS-SR16 assessment has been used to screen for depression and also to measure symptom severity. This scale is also used to distinguish response from remission, as well as to quantify between group treatments effects in open label and randomized controlled trials. The patient is asked to rate the severity and frequency of specific symptoms present over the last 7 days. The QIDS-SR16 total scores range from 0 to 27. Higher scores indicate greater severity of impairment

  • Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6. [ Time Frame: Baseline and Week 6. ] [ Designated as safety issue: No ]
    The SDS comprises patient-rated items designed to measure the extent to which the subject's life is impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities, are impaired by his or her symptoms on 10-point visual analogue scales from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment. There are verbal descriptors for the points on the scales as well as numerical scores that provide more precise levels of the verbal descriptors. In addition, the SDS addresses the number of days lost and the number of days under-productive due to the symptoms.


Estimated Enrollment: 312
Study Start Date: December 2011
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramelteon SL (Dose 1) QD Drug: Ramelteon SL
Ramelteon SL tablets, sublingual, once daily, at night time for up to 8 weeks.
Other Name: TAK-375SL
Experimental: Ramelteon SL (Dose 2) QD Drug: Ramelteon SL
Ramelteon SL tablets, sublingual, once daily, at night time for up to 8 weeks.
Other Name: TAK-375SL
Experimental: Ramelteon SL (Dose 3) QD Drug: Ramelteon SL
Ramelteon SL tablets, sublingual, once daily, at night time for up to 8 weeks.
Other Name: TAK-375SL
Placebo Comparator: Placebo QD Drug: Placebo
Ramelteon placebo-matching tablets, sublingual, once daily, at night time for up to 8 weeks.

Detailed Description:

Ramelteon sublingual formulation is being developed by Takeda Pharmaceutical Company Limited for maintenance therapy of Bipolar I disorder.

Participants will be seen twice during the first week of treatment, weekly during the first 2 weeks of treatment and then every 2 weeks up to the end of the 8-week treatment period. Participants who complete the 8-week treatment period will have a follow-up visit approximately seven days after the last visit. A safety follow-up phone call will be made 30 days after completion of the 8-week treatment period.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant is a man or woman aged between 18 and 75 years, inclusive.
  4. The participant suffers from Bipolar I Disorder, Most Recent Episode Depressed as the primary diagnosis according to DSM-IV-TR criteria (classification code 296.5x) and confirmed by the Structured Clinical Interview for DSM Disorders (SCID).
  5. The reported duration of the current Major Depressive Episode (MDE) is at least four weeks and less than 12 months.
  6. The participant has a YMRS score of ≤10 both at the Screening and Baseline visits.
  7. The participant has a MADRS total score ≥24 at the Screening and Baseline Visits.
  8. The participant has a CGI-S score of ≥4 at the Screening and Baseline Visits.
  9. HAM-A score is ≤21 at Screening and Baseline visits.
  10. The participant has a lithium and/or valproate levels within therapeutic range (0.6 - 1.2 mEq/L for lithium or 50-125 mcg/ml for valproate) at screening. If the patient does not have a lithium and/or valproate level within therapeutic range at screening, they must have a lithium and/or valproate levels within the therapeutic range between Day - 15 to Day -30 of screening.
  11. A female participant of childbearing potential who is sexually active and agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose.
  12. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent through the duration of the study and for 30 days after the last dose.

Exclusion Criteria:

  1. The participant has received any investigational compound <30 days before Screening or 5 half-lives prior to Screening.
  2. The participant has received ramelteon in a previous clinical study or has ever used ramelteon.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  4. The participant has one or more of the following:

    • Any current psychiatric disorder other than Bipolar I Disorder, Most Recent Episode Depressed as defined in the DSM-IV-TR, as assessed by the SCID.
    • Current or history of: schizophrenia, unipolar depression with psychotic features, bipolar depression with psychotic features, any other psychotic disorder (with the exception of psychosis associated with a manic episode), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least one year from the day of screening. (Participant must also have negative urine drug screen prior to Baseline).
    • Presence or history of a clinically significant neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder that might compromise the study.
    • History of Rapid Cycling Bipolar Disorder: Patients who have more than 8 episodes of mood disorder per year.
  5. The participant experienced the first episode of mood disorder after the age of 65 years.
  6. The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate treatment trials with any of the mood stabilizers (specifically started to treat the current depressive episode) and/or antidepressant medications of at least 6 weeks duration each.
  7. The participant is on any other psychotropic medications except for lithium (serum levels 0.8 to mEq/L) or valproate (serum levels 50 to 125 mcg/ml) at the Screening visit.
  8. The participant is on lithium and/or valproate for less than 30 days prior to screening.
  9. If the participant is on antidepressant medications and/or antipsychotic medications (used as a mood stabilizer) and the patient is considered appropriate by the PI, these medications must be washed out for at least 2 weeks prior to the Screening visit.
  10. The participant has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
  11. The participant has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days prior to screening or plans to initiate such therapy during the study.
  12. The participant has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥ 5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
  13. The participant has taken or is anticipated that the participant will take at least 1 of the disallowed concomitant medications.
  14. The participant has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance as determined by Investigator.
  15. The participant has a history or current diagnosis of Fibromyalgia, Chronic Fatigue Syndrome, Chronic Pain Syndrome or Sleep apnea.
  16. The participant has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication. This criterion does not include those participants with basal cell or stage I squamous cell carcinoma of the skin.
  17. The participant has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:

    • A serum creatinine value >1.5 times the upper limits of normal (xULN).
    • A serum total bilirubin value >1.5 xULN.
    • A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 xULN.
  18. The participant has glycosylated hemoglobin (HbA1C) ≥7% at baseline and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known diabetes are not excluded.
  19. The participant has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. If TSH is outside the normal range, a free T4 will be obtained.
  20. The participant has clinically significant abnormal vital signs as determined by the investigator.
  21. The participant has an abnormal electrocardiogram (ECG) as determined by the central reader and confirmed as clinically significant by the investigator.
  22. The participant has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  23. The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01467700

Contacts
Contact: Takeda Study Registration Call Center 800-778-2860 medicalinformation@tpna.com

  Hide Study Locations
Locations
United States, Alabama
Recruiting
Birmingham, Alabama, United States
Recruiting
Dothan, Alabama, United States
United States, Arkansas
Not yet recruiting
Fayetteville, Arkansas, United States
Recruiting
Little Rock, Arkansas, United States
United States, California
Recruiting
Costa Mesa, California, United States
Recruiting
Garden Grove, California, United States
Not yet recruiting
Irvine, California, United States
Recruiting
National City, California, United States
Recruiting
Oceanside, California, United States
Recruiting
Orange, California, United States
Recruiting
Paramount, California, United States
Recruiting
San Diego, California, United States
Recruiting
Santa Ana, California, United States
Recruiting
Sherman Oaks, California, United States
Recruiting
Torrance, California, United States
Recruiting
Wildomar, California, United States
United States, Colorado
Recruiting
Colorado Springs, Colorado, United States
Recruiting
Denver, Colorado, United States
United States, Connecticut
Recruiting
Norwalk, Connecticut, United States
United States, District of Columbia
Recruiting
Washington, District of Columbia, United States
United States, Florida
Recruiting
:Leesburg, Florida, United States
Not yet recruiting
Fort Myers, Florida, United States
Recruiting
Jacksonville, Florida, United States
Completed
Miami, Florida, United States
Recruiting
Orange City, Florida, United States
Not yet recruiting
Orlando, Florida, United States
Recruiting
Tampa, Florida, United States
United States, Georgia
Recruiting
Atlanta, Georgia, United States
Not yet recruiting
Marietta, Georgia, United States
Recruiting
Smyrna, Georgia, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
Not yet recruiting
Hoffman Estates, Illinois, United States
Not yet recruiting
Libertyville, Illinois, United States
Recruiting
Skokie, Illinois, United States
United States, Indiana
Recruiting
Indianapolis, Indiana, United States
United States, Kansas
Not yet recruiting
Wichita, Kansas, United States
United States, Louisiana
Completed
Shreveport, Louisiana, United States
United States, Maryland
Not yet recruiting
Baltimore, Maryland, United States
United States, Massachusetts
Recruiting
Boston, Massachusetts, United States
United States, Michigan
Recruiting
Bloomfield Hills, Michigan, United States
United States, Mississippi
Recruiting
Flowood, Mississippi, United States
United States, Missouri
Recruiting
St Louis, Missouri, United States
United States, Nebraska
Recruiting
Lincoln, Nebraska, United States
United States, Nevada
Recruiting
Las Vegas, Nevada, United States
United States, New Jersey
Recruiting
Cherry Hill, New Jersey, United States
United States, New Mexico
Not yet recruiting
Albuquerque, New Mexico, United States
United States, New York
Not yet recruiting
Brooklyn, New York, United States
Recruiting
Cedarhurst, New York, United States
Recruiting
Fresh Meadows, New York, United States
Recruiting
New York, New York, United States
Recruiting
Rochester, New York, United States
Recruiting
Staten Island, New York, United States
United States, North Carolina
Recruiting
Charlotte, North Carolina, United States
Recruiting
Durham, North Carolina, United States
Recruiting
Raleigh, North Carolina, United States
United States, Ohio
Recruiting
Cincinnati, Ohio, United States
Recruiting
Cleveland, Ohio, United States
Recruiting
Dayton, Ohio, United States
United States, Oklahoma
Recruiting
Oklahoma City, Oklahoma, United States
United States, Oregon
Recruiting
Portland, Oregon, United States
United States, Pennsylvania
Recruiting
Allentown, Pennsylvania, United States
Recruiting
Media, Pennsylvania, United States
United States, Rhode Island
Recruiting
Lincoln, Rhode Island, United States
United States, South Carolina
Completed
Charleston, South Carolina, United States
United States, Tennessee
Recruiting
Memphis, Tennessee, United States
Not yet recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Austin, Texas, United States
Recruiting
Dallas, Texas, United States
Recruiting
Houston, Texas, United States
Recruiting
Irving, Texas, United States
Not yet recruiting
Plano, Texas, United States
Not yet recruiting
San Antonio, Texas, United States
United States, Washington
Recruiting
Kirkland, Washington, United States
Recruiting
Richland, Washington, United States
Recruiting
Seattle, Washington, United States
United States, Wisconsin
Recruiting
Milwaukee, Wisconsin, United States
Argentina
Not yet recruiting
Bogota, Argentina
Recruiting
Buenos Aires, Argentina
Not yet recruiting
Cordoba, Argentina
Recruiting
Mendoza, Argentina
Not yet recruiting
Santa Fe, Argentina
Canada
Recruiting
Oceanside, Canada
Chile
Recruiting
Antofagasta, Chile
Not yet recruiting
Arauco, Chile
Not yet recruiting
Elqui, Chile
Recruiting
Santiago, Chile
Colombia
Recruiting
Bello, Antioquia, Colombia
Recruiting
Antioquia, Colombia
Recruiting
Barranquilla, Colombia
Recruiting
Bello, Colombia
Not yet recruiting
Bogota, Colombia
Recruiting
Bogotá, Colombia
Mexico
Recruiting
Mexico, DF, Mexico
Recruiting
Jalisco, Guadalajara, Mexico
Recruiting
Leon, Guanajuato, Mexico
Recruiting
Monterrey, Nuevo Leon, Mexico
Recruiting
Merida, Yucatan, Mexico
Not yet recruiting
Baja California, Mexico
Recruiting
Guanajuato, Mexico
Recruiting
Jalisco, Mexico
Not yet recruiting
Jalisco, Mexico
Recruiting
Merida, Mexico
Not yet recruiting
Mexico City, Mexico
Recruiting
Nuevo Leon, Mexico
Not yet recruiting
San Luis Potosi, Mexico
Recruiting
San Luis Potosi, Mexico
Not yet recruiting
Sinaloa, Mexico
Not yet recruiting
Tepetlacalco, Mexico
Peru
Not yet recruiting
Lima, Peru
Not yet recruiting
Lincoln, Peru
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Clinical Science Takeda
  More Information

Additional Information:
No publications provided

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01467700     History of Changes
Other Study ID Numbers: TAK-375SL_201, U1111-1122-7380
Study First Received: November 4, 2011
Last Updated: July 18, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 18, 2014